T1	Participants 45 123	patients with chronic hepatitis C treated with interferon-alpha and ribavirin:
T2	Participants 300 408	patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin
T3	Participants 514 557	untreated patients with chronic hepatitis C
T4	Participants 953 1001	patients in the control and the amantadine group
